InSingulo offers a label‑free, single‑molecule biosensing platform that measures binding events directly on proteins embedded in their native cell membranes, delivering both affinity and kinetic parameters in a single assay. The patented dISA technology enables high‑sensitivity analysis of challenging targets such as GPCRs, ion channels, and intrinsically disordered proteins without the need for fluorescent tags, and is available as the Luma One instrument, a fee‑for‑service analysis, or an emerging GPCR efficacy platform.
Funding
$6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Drug discovery often requires studying proteins, especially membrane proteins and intrinsically disordered proteins, in their native membrane environment. Conventional biosensing assays typically need protein labeling or removal from the membrane, which can alter binding behavior and limit sensitivity, making it difficult to obtain accurate kinetic and thermodynamic data for challenging targets and modalities.
Solution
InSingulo provides a label‑free, single‑molecule biosensing platform that measures binding events directly on proteins embedded in their native cell membranes. The patented dISA technology detects individual binding events without the need for fluorescent or other tags, delivering both affinity and kinetic parameters in a single assay. By preserving the protein’s natural conformation, the system yields reliable data for membrane proteins, intrinsically disordered proteins, protein‑protein interactions, and a wide range of therapeutic modalities including fragments, peptides, antibodies, and oligonucleotides. The platform is offered as the Luma One instrument with compatible biosensor plates, as a fee‑for‑service kinetic analysis service, and as a developing quantitative efficacy platform for GPCR signaling pathways.
Target Audience
Primary customers are pharmaceutical and biotech companies, as well as academic research labs, that need high‑sensitivity, label‑free kinetic data for membrane proteins, protein‑protein interactions, and emerging therapeutic modalities.
Features
- Label‑free detection of single‑binding events on proteins in their native membrane environment
- Single‑molecule sensitivity enabling accurate measurement of low‑affinity and low‑abundance interactions
- Compatibility with challenging targets such as GPCRs, ion channels, intrinsically disordered proteins, and protein‑protein interactions
- Ability to assay diverse modalities (fragments, covalent fragments, small molecules, peptides, antibodies, oligonucleotides) without dependence on molecular weight
- Integrated kinetic and thermodynamic analysis delivering association/dissociation rates and binding affinities in one assay
- Luma One instrument with proprietary biosensor plates for on‑site measurements
- Fee‑for‑service offering with rigorous data analysis and quality control for external users
- Emerging GPCR efficacy platform that measures downstream G‑alpha signaling while keeping receptors in the apo state